[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-related-fatigue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-related-fatigue":308},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,55,81,108,138,171,200,228,253,285],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100585686","phase-3-methylphenidate-in-pediatric-brain-tumor-survivors-with-cancer-related-fatigue-100585686",false,"NCT06905587","Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue","Effect of Methylphenidate on Cancer-related Fatigue in Patients Treated for a Brain Tumor During Childhood or Adolescence: Protocol for a Randomized, Double-blind, Placebo-controlled Crossover Trial - the EMBRAIN Trial","EMBRAIN","Inclusion Criteria:\n\n1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).\n2. Treated for a PBT during the previous 10 years, starting from date of diagnosis.\n3. Aged ≥6 years 0 months at the start of the trial.\n4. Off therapy\u002Factive treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.\n5. No known signs of clinical or radiological tumor progression at last follow-up.\n6. Danish is the sole or primary language (enabling provision of validated assessment tools).\n7. Patient and family have provided consent for inclusion in the trial.\n8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.\n9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.\n\nExclusion Criteria:\n\n1. Any known contraindications to methylphenidate as outlined below:\n\n   A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.\n2. History of recent poorly controlled seizures.\n3. Motor tics or Tourette syndrome (including family history of tic disorder).\n4. Known diagnosis of Attention Deficit\u002FHyperactivity Disorder or Autism Spectrum Disorder.\n5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of \\\u003C50.\n6. Pregnancy. Participants known to be pregnant or breastfeeding at screening\u002Fregistration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.\n7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately\u002Fconcerns about familial substance abuse.\n8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).\n9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.","ALL","6 Years","27 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.\n\nThe researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit\u002Fhyperactivity disorder (ADHD).\n\nIf methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.",[28,29,30],"Brain Tumor, Pediatric","Cancer-related Fatigue","Methylphenidate",[32,33,34,35,36,37,38,39,40,41],"methylphenidate","cancer-related fatigue","brain tumor","childhood cancer","pediatric cancer","childhood cancer survivor","late effect","long-term effects secondary to cancer therapy in children","long-term effects of cancer-treatment","pediatric brain tumor","RECRUITING","2026-06-23",{"date":45,"type":46},"2026-06-26","ACTUAL",{"date":48,"type":46},"2025-09-02",{"date":50,"type":22},"2029-12",{"name":52,"class":53},"Odense University Hospital","OTHER",4,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100633649","feasibility-and-expansion-trial-of-transcutaneous-vagus-nerve-stimulation-tvns-for-immune-related-fatigue-in-patients-receiving-immune-checkpoint-inhibitors-100633649","NCT07529431","Feasibility and Expansion Trial of Transcutaneous Vagus Nerve Stimulation (tVNS) for Immune-Related Fatigue in Patients Receiving Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Age 18 years or older\n* Histologically confirmed advanced or metastatic solid tumor\n* Receiving immune checkpoint inhibitor therapy and completed at least two cycles\n* Clinically significant fatigue (FACIT-F score ≤ 34)\n* ECOG performance status 0-2\n* Life expectancy of at least 3 months\n* Ability to provide informed consent\n* Access to a smartphone or tablet\n\nExclusion Criteria:\n\n* Current or planned chemotherapy, targeted therapy, or radiation during the 4-week intervention period.\n* Have received targeted therapy in the last 2 weeks\n* Have received chemotherapy or radiation therapy in the last 4 weeks\n* Symptomatic brain metastases defined as active neurologic complaint (headache, blurry vision, neurologic deficits or other symptom requiring treatment with steroids)\n* Long term steroid use \\>10 mg prednisone equivalent daily\n* Active autoimmune disease requiring systemic immunosuppression\n* Implanted electronic medical devices (e.g., pacemakers, defibrillators)\n* History of epilepsy or vagal hypersensitivity\n* Known arrhythmia or bradycardia (Baseline HR \\\u003C 50 bpm)\n* Open wounds or dermatologic issues at the stimulation site\n* Pregnancy or breastfeeding\n* Participation in other fatigue-focused intervention trials\n* Severe uncontrolled psychiatric illness (PHQ-9 \\>20)","18 Years",{"count":63,"type":22},13,[65],"NA","This study evaluates whether a non-invasive device called transcutaneous vagus nerve stimulation (tVNS) can be safely and feasibly used to help reduce fatigue in patients receiving immunotherapy for cancer. Fatigue is a common and often severe side effect of immune checkpoint inhibitors, and there are currently limited effective treatment options.\n\nIn this study, participants will use a small device at home that delivers mild electrical stimulation to the ear for 60 minutes each day over a 6-week period. The study will assess whether patients are able to use the device as prescribed (feasibility), how well it is tolerated, and whether it may improve fatigue and quality of life.\n\nThe study will also explore changes in biological markers of inflammation and measures of nervous system function to better understand how tVNS may work. The results of this study will help determine whether this approach should be tested in larger future trials.",[29],[69,70],"Cancer-related fatigue","Vagus nerve stimulation","NOT_YET_RECRUITING","2026-04-07",{"date":74,"type":46},"2026-04-14",{"date":76,"type":22},"2026-07-01",{"date":78,"type":22},"2035-07",{"name":80,"class":53},"University of Vermont Medical Center",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100633643","feasibility-of-exercise-for-cancer-patients-and-healthy-eating-timeframes--100633643","NCT07529353","Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' .","Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' (EXCAP-hEAT) Among Breast Cancer Survivors Receiving Adjuvant Endocrine Therapy.","EXCAP-hEAT","Inclusion Criteria:\n\n* Must be aged 18 years or older\n* Must have a confirmed diagnosis of breast cancer (stage I-IIIC)\n* Must have completed adjuvant chemotherapy, surgery, and\u002For radiation for cancer at least 2 - 120 months prior to enrolling,\n* Must be prescribed adjuvant endocrine therapy,\n* Must have a baseline level of fatigue, as determined by reporting a score of 4 or higher on the Symptom Inventory\n* Must have a body mass index greater than or equal to 25 kg per meter squared\n* Must have the ability to ambulate independently\n* Must be willing and able to participate in home-based exercise and eating timeframe intervention\n* Must have the ability to read and understand the English language,\n\nExclusion Criteria:\n\n* Must not have metastatic or recurrent breast cancer\n* Must not be currently receiving chemotherapy or radiation therapy\n* Must not have a medical condition that would preclude safe participation in intervention or study procedures\n* Must not be pregnant, or planning to become pregnant during the study period\n* Must not be in the active or maintenance stage of exercise behavior as assessed by the Exercise Stages of Change Short Form,\n* Must not have any condition that in the opinion of the investigator would interfere with participation or safety\n* Must not be currently using, or plan to initiate use of prescription or over-the-counter weight-loss medications",{"count":90,"type":22},20,[65],"This study evaluates the feasibility and preliminary effects of a home based exercise and activity program for individuals with cancer. Participants will engage in a structured intervention designed to support physical activity and symptom management. The study will assess changes in patient reported outcomes, functional measures, and overall adherence to the program. Findings will help determine whether this approach is practical and potentially beneficial for improving health related outcomes in this population.",[94,95],"Breast Cancer","Cancer Related Fatigue",[97,98,99],"Breast Cancer Survivorship","Home Based Exercise","Fatigue Management",{"date":74,"type":46},{"date":102,"type":22},"2026-04",{"date":104,"type":22},"2028-04",{"name":106,"class":53},"University of Rochester",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100593038","phase-2-telehealth-exercise-program-evaluating-fatigue-and-physical-function-in-rural-cancer-survivors-100593038","NCT07001241","Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors","Effects of a Telehealth Exercise Program for Rural Cancer Survivors With Cancer-related Fatigue Including Integrated Longitudinal Assessments of Objective Physical Function and Fatty Acid Oxidation","Inclusion Criteria:\n\n1\\. Age ≥ 18 and \\\u003C 90 years of age. 2. Diagnosis of breast or prostate cancer. 3. Cancer treatment criteria: 3a. Completion of treatment with curative intent \\> 3 months prior to and \\\u003C 5 years from study initiation.\n\n3b. Treatment must include hormonal, radiation, chemotherapy, and\u002For immunotherapy. Those who have received only surgery are not eligible.\n\n3c. Individuals diagnosed with breast cancer currently receiving maintenance hormonal therapy, with no planned treatment changes in the next six months, are eligible.\n\n4\\. Home zip code meeting Health Resources \\& Services Administration (HRSA) definition of rural (data.hrsa.gov\u002Ftools\u002Frural-health).\n\n5\\. Presence of at least moderate fatigue (\\>3\u002F10 per National Comprehensive Cancer Network guidelines).\n\n6\\. Access to high-speed home internet. 7. Possession of smartphone or laptop with front-facing camera. 8. Capable and willing to give informed consent. 9. Willing to participate in a 12-week telehealth exercise intervention or 12-week waiting period prior to intervention with brief remote physical assessments and dried blood spot collection every 2 weeks.\n\n10\\. Able and willing to provide contact information for a local support individual to assist with any possible adverse events.\n\n11\\. Able and willing to provide contact information for a local primary care provider to address medical issues potentially arising during study activities.\n\n12\\. Able to provide signed physician clearance for exercise if indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) or National Comprehensive Cancer Network exercise safety screening questions.\n\nExclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) Performance Status Grade ≥ 2.\n2. Current or planned cancer-related treatments (except maintenance hormonal therapies) in the next six months.\n\n2a. For individuals with a prostate cancer diagnosis, those currently receiving androgen deprivation therapy (ADT), or those who have previously received ≥ 12 months of ADT, are not eligible.\n\n3\\. Plans to relocate to a non-rural location in the next six months. 4. Presence of a disease or condition that affects the ability of an individual to safely participate in an exercise intervention (e.g. recent cardiac event or chronic obstructive pulmonary disease).\n\n4a. These conditions are identified in the PAR-Q+. 5. Presence or history of metabolic disease (e.g. diabetes or uncontrolled hyper- or hypothyroidism).\n\n5a. Participants with pre-diabetes, metabolic syndrome, or diabetes managed with metformin only will be eligible, with this variable tracked for later analysis.\n\n6\\. Current participation in another exercise oncology program.","89 Years",{"count":117,"type":22},134,[119],"PHASE2","This study investigates the efficacy of a telehealth exercise program designed specifically for rural cancer survivors with cancer-related fatigue (CRF). Small dried blood samples and measures of physical function will be collected throughout the program. The main questions it aims to answer are:\n\n* Does the exercise program improve CRF in rural cancer survivors?\n* How do CRF, metabolism, and physical function change during the exercise program? Researchers will compare the program to a wait-list control group. This group will complete all study measures without without changing current physical activity before receiving the full exercise program.\n\nParticipants will:\n\n* Complete a virtual physical assessment before and after the program.\n* Complete brief virtual assessments and collect dried blood samples (at home and mailed in) every two weeks during the program.\n* Receive a personalized exercise program including virtual sessions and remote exercise programming with a cancer exercise specialist (after a 12-week wait period in the wait-list control group).\n* Optional: Willing participants will visit a study site for a laboratory-based exercise assessment before and after the program.",[29,94,122],"Prostate Cancer",[122,124,125,94,126,127],"Exercise","Telehealth","Metabolism","Physical function","2026-02-02",{"date":130,"type":46},"2026-02-05",{"date":132,"type":46},"2025-10-08",{"date":134,"type":22},"2030-12",{"name":136,"class":53},"University of Colorado, Denver",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":61,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100618904","wearable-technology-supported-exercise-program-for-fatigue-and-quality-of-life-in-pediatric-cancer-patients-we-ex-pedsca-100618904","NCT07337681","Wearable Technology-Supported Exercise Program for Fatigue and Quality of Life in Pediatric Cancer Patients (WE-EX PedsCa)","Effect of a Wearable Technology-Supported Exercise Program on Fatigue and Health-Related Quality of Life in Pediatric Cancer Patients: A Randomized Controlled Trial","WE-EX PedsCa","Inclusion Criteria:\n\n* Aged 13 to 18 years.\n* Diagnosed with cancer and followed at a pediatric hematology-oncology clinic.\n* Currently receiving active cancer treatment and has completed at least one cycle of chemotherapy.\n* Clinically stable and medically cleared by the treating physician to participate in low-to-moderate intensity exercise.\n* Able to understand instructions and communicate verbally.\n* Willing to participate in at least 75% of the prescribed exercise sessions.\n* Written informed consent obtained from a parent or legal guardian and assent obtained from the participant.\n\nExclusion Criteria:\n\n* Presence of acute infection, uncontrolled cardiac or pulmonary disease, respiratory failure, or uncontrolled hypertension.\n* Severe neurological, psychiatric, or musculoskeletal conditions that limit safe participation in exercise.\n* Persistent thrombocytopenia (\\\u003C10,000\u002FµL) or known coagulation disorders.\n* Uncontrolled seizure disorders.\n* Central nervous system metastases.\n* Any medical or psychological condition deemed by the treating physician to contraindicate exercise participation or compromise study procedures.","13 Years",{"count":21,"type":22},[65],"Children and adolescents receiving cancer treatment often experience fatigue, reduced physical activity, and decreased quality of life. Although exercise has been shown to reduce these problems, maintaining regular and safe physical activity during cancer treatment can be difficult due to treatment side effects, safety concerns, and limited access to supervised programs.\n\nThis study aims to evaluate the feasibility, safety, and effectiveness of a wearable technology-supported exercise program on fatigue and health-related quality of life in pediatric cancer patients aged 13 to 18 years. Participants will be randomly assigned to either an intervention group or a control group. The intervention group will participate in an 8-week structured exercise program delivered through a mobile application, including video-guided exercise sessions performed three times per week and monitored continuously using a wearable activity tracker. The control group will receive standard care and will wear the activity tracker for passive monitoring only.\n\nFatigue and quality of life will be assessed at baseline, mid-intervention, and after completion of the program. Physical activity, heart rate, sleep patterns, and adherence to the exercise program will be objectively monitored using wearable devices. The findings from this study are expected to provide evidence on whether a digitally delivered, wearable-supported exercise program is a feasible and beneficial approach to improving well-being in children and adolescents undergoing cancer treatment.",[151,29,152,124],"Pediatric Cancer","Quality of Life",[154,155,156,157,158,33,159,160,161],"Pediatric oncology","adolescent cancer","wearable technology","exercise intervention","physical activity","health-related quality of life","mobile health","digital exercise program","2026-01-12",{"date":164,"type":46},"2026-01-13",{"date":166,"type":22},"2026-03",{"date":168,"type":22},"2026-05",{"name":170,"class":53},"Istanbul University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":17,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":107},"100605175","early-phase-1-tdcs-for-cancer-related-fatigue-and-weakness-100605175","NCT07159100","tDCS for Cancer-Related Fatigue and Weakness","Neuromodulation as a Therapeutic Intervention to Improve Cancer Related Fatigue and Weakness","General Inclusion - All participants\n\n1. Aged 40-80\n2. Right Handed, as determined by the Edinburgh Inventory 21\n3. Proficient in English\n4. Must be available for the familiarization, and testing sessions\n\nGeneral Inclusion - Cancer Patients only\n\n1. Cancer (\\>6 months post therapy)\n2. Suffers from a subjective feeling of cancer related fatigue and weakness as assessed by the following question: \"Do you suffer from symptoms of fatigue and weakness related to your cancer or cancer treatment?\"\n3. Have had cancer diagnosis and treatment in the past\n4. Must have a stable physical\u002Fhealth condition for the past 3 months with no expected changes for the duration of the study\n\nGeneral Exclusion - All participants\n\n1. Neurological, psychiatric, musculoskeletal or other types of disorder not caused by cancer and\u002For cancer treatment, which may affect participants sensorimotor function and cognitive abilities\n2. No consciousness to understand and sign informed consent voluntarily\n3. History of alcohol, and illicit drug use\n4. History of smoking within the last 5 years.\n\nGeneral Exclusion - Cancer Patients 1. Radiation, surgery, chemo, or other cancer treatment therapies in the past 6 months prior to enrollment. Hormonal maintenance treatment is allowed.\n\nGeneral Exclusion - Healthy Participants\n\n1\\. History of cancer or cancer treatment\n\nExclusion criteria related to tDCS and TMS safety - All participants\n\n1. History of epilepsy or unprovoked seizures\n2. Family history of epilepsy (father, mother, children, siblings with diagnosis of epilepsy)\n3. Active migraine headaches\n4. Past or current history of treated tinnitus or severe hearing problems\n5. Implanted medical devices (pacemakers, defibrillators, medical pump, implanted brain stimulator, aneurysm clip, carotid or cerebral stents, central venous catheter, non-removable hearing aids)\n6. Damage to the skin on the scalp\n7. History of mental illness (schizophrenia, anxiety, major depression, manic disorders)\n8. Tattoo with metal based ink in the head or neck\n9. Currently taking or withdrawing from any central nervous system active medication (stimulants, anticonvulsants, antidepressants, psychotropic medications).\n10. Pregnant as determined by a Pregnancy test for non-menopausal (no menstruation for at least 1 year) women younger than 55 years (for TMS and fMRI only).\n\nExclusion criteria related to MRI safety - All participants\n\nWe will be using the Kessler Foundation RONIC MRI center screening form to screen participants for the MRI scan. Exclusion criteria includes:\n\n1. Suffer from claustrophobia (fear of confined spaces)\n2. Prior injury to the eye involving a metallic object or fragment (e.g., metallic slivers, shavings, foreign body, etc.)?\n3. Presence or prior injury by a metallic object, or foreign body or metallic fragment (e.g., BB, bullet, shrapnel, etc.)\n4. Currently or former metal worker (welder, machinist, etc.)\n5. Implanted electrical devices (e.g. pacemakers, defibrillators or ICD)\n6. Implanted stimulators or internal electrodes or wires (neurostimulator, brain stimulator, spinal cord, bone growth\u002Fbone fusion)\n7. Aneurysm clips (metal clips on the wall of a large artery), metallic stent, shunt (spinal)\n8. Metallic prostheses or implants (including metal pins and rods, plate, screw, surgical staples, clips or metallic sutures, joint replacement (hip, knee), cochlear or other otologic implant, eye, penile, heart valves, eyelid spring or wires, prosthetic limbs)\n9. Dental implants, dentures or partial plates (regular filling, amalgam and crown are OK)\n10. Insulin, medication or other infusion pumps\n11. Radiation seeds or implants\n12. Transdermal medication patch (Nitroglycerine, Nicotine)\n13. IUD, diaphragm or pessary\n14. Tissue expander (e.g. breast)\n15. Body tattoos or permanent makeup (eyeliner, lip) if deemed unsafe in the MRI\n16. Body piercing",true,"40 Years","80 Years",{"count":182,"type":22},75,[184],"EARLY_PHASE1","This pilot study investigates the effectiveness of non-invasive brain stimulation (tDCS) in alleviating cancer-related fatigue (CRF) and muscle weakness. Using a randomized, double-blind crossover design, participants perform fatiguing muscle tasks with and without tDCS, and outcomes include task endurance, maximal voluntary contraction force, and neuromuscular markers. Neural mechanisms will be assessed via EEG, TMS, and MRI.",[29,187],"Neuromodulation",[189,69,190],"tDCS","neuromodulation","2025-08-28",{"date":193,"type":46},"2025-09-08",{"date":195,"type":22},"2025-09-10",{"date":197,"type":22},"2027-12-31",{"name":199,"class":53},"Kessler Foundation",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":107},"100473079","phase-2-pg2-injection-for-the-treatment-of-moderate-to-severe-fatigue-in-breast-cancer-patients-100473079","NCT05440227","PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients","A Phase II, Double Blind, Randomized, Placebo-controlled Study of PG2 Injection for the Treatment of moderate-to Severe Fatigue in Patients With Locally Advanced, Recurrent, or Metastatic Breast Cancer Who Are Receiving Infusional Chemotherapy","Inclusion Criteria:\n\n1. Women aged ≥ 20 years\n2. ECOG performance score ≤ 2\n3. Locally advanced, recurrent or metastatic, histologically documented breast cancer who is currently undergoing infusional chemotherapy regimen.\n4. Presence of moderate to severe cancer related fatigue prior to randomization as defined by at least two records of usual fatigue score ≥ 4 on the numeric scale (0 -10), which must be ≥ 14 days apart.\n5. Laboratory values obtained prior to randomization:\n\n   * Hgb ≥ 10 g\u002FdL (patients must not be transfused ≤ 14 days to meet this criterion)\n   * Creatinine ≤ 1.2 x ULN\n   * AST (SGOT) or ALT (SGPT) ≤1.5 x ULN (or ≤5.0 x ULN for patients with liver metastases)\n6. Pain under controlled of score ≤ 4 on the numeric scale (0 -10)\n7. Life expectancy ≥ 3 months\n8. Ability to complete patient questionnaires alone or with assistance.\n9. Negative pregnancy test done ≤ 14 days prior to randomization, for women of childbearing potential only, and willing to take efficient contraceptives procedures to avoid pregnancy throughout the study period.\n10. Willing to provide written informed consent and agree to follow the study requirements.\n\nExclusion Criteria:\n\n1. Known brain metastasis or primary CNS malignancy\n2. Has known psychiatric or substance abuse disorders.\n3. Malnutrition, active infection, uncontrolled thyroid disorder, uncontrollable hypertension or diabetes mellitus, significant pulmonary disease and cardiovascular disease.\n4. Currently using any other pharmacologic agents.\n5. Subject who is unwilling to receive transfusions when, at the investigator's discretion, it is required to control her anemia.\n6. Other medical conditions that necessitate chronic systemic use of steroids (e.g. use of prednisolone \\> 10 mg daily or equivalent steroids fore more than 2 weeks).\n7. ≤ 4 weeks from major surgery to randomization, including any procedure that requires general anesthetics.\n8. Pain requiring opioid pain medication, however, over the counter analgesics such as acetaminophen or ibuprofen are allowed.\n9. Use of monoamine oxidase inhibitors (MAOI) (such as Moclobemide).\n10. Planning to start or complete any type of cancer therapy during the 8 weeks course of the study, once randomized on the study.\n11. Use of any over the counter herbal\u002Fdietary supplement marketed for fatigue or energy.\n12. Known history of hypersensitivity to Astragalus products.\n13. Currently participating another interventional study or planning to join one in the upcoming 8 weeks after randomization.\n14. Currently breast feeding.\n15. With any other serious disease considered by the investigator not in the condition to enter into the trial.","FEMALE","20 Years",{"count":210,"type":22},36,[119],"The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.",[29],[215,216,217],"breast cancer","fatigue","CRF","2025-06-02",{"date":220,"type":46},"2025-06-05",{"date":222,"type":46},"2023-05-17",{"date":224,"type":22},"2026-06",{"name":226,"class":227},"PhytoHealth Corporation","INDUSTRY",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":178,"sex":17,"minAge":61,"maxAge":180,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":107},"100345077","research-for-pathophysiology-of-cancer-related-fatigue-crf-and-chronic-fatigue-cfsme-100345077","NCT03773003","Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME)","Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME) by Lipidomics, Metabolomics, Microbiome and Exome Analysis and Investigation of Clinical Improvement Under Administration of Probiotics","IMPROFA","Inclusion Criteria:\n\n* histologically, cytologically or radiologically confirmed tumor disease\n* indication for chemotherapy\n* Written consent to participation\n\nExclusion Criteria:\n\n* chronic-inflammatory bowel disease\n* pregnancy",{"count":237,"type":22},150,[65],"Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS\u002FME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome Analysis and Investigation of a Possible Benefit of Probiotics.",[95,241],"Fatigue Syndrome, Chronic",[243],"Cancer Fatigue, Chronic Fatigue","2025-05-22",{"date":246,"type":46},"2025-05-29",{"date":248,"type":46},"2021-07-20",{"date":250,"type":22},"2025-12-01",{"name":252,"class":53},"Universität des Saarlandes",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":284},"100562172","the-effects-of-a-food-product-containing-mushroom-extracts-andosantm-in-subjects-with-colorectal-cancer-related-fatigue-100562172","NCT06599710","The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects with Colorectal Cancer-related Fatigue","Pilot Study to Evaluate the Effects of a Food Product Containing Mushroom Extracts (AndosanTM) in Subjects with Colorectal Cancer-Related Fatigue","Inclusion Criteria:\n\n1. Males and females from 18 to 65 years of age\n2. Caucasian\n3. Diagnosis of non-metastatic colorectal cancer (stages I-III) (documented)\n4. Diagnosis of persistent cancer-related fatigue with moderate or severe symptoms of cancer-related fatigue (≥ 4 on 0-10 Numerical Rating Scale (NRS) and a Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Fatigue subscale (FACIT-F FS) score of ≤ 34 for assessment of average fatigue in the week before visit 1, both assessed at visit 1)\n5. Cancer-related fatigue present since at least 4 weeks before visit one at a stable level (self-reported)\n6. Cancer treatment completed (as reported by the attending physician before the study) considering the following conditions:\n\n   * a minimum of 4 weeks after the end of the last cancer-related therapy (e.g. chemotherapy, radiotherapy)\n   * a minimum of 6 weeks after any cancer-related surgery (if any)\n7. Serum C-reactive protein (CRP) levels greater than 3 mg\u002Fl at visit1\u002F Screening\n8. Stable medication for comorbidities (if any)\n9. Established cancer-related fatigue management regime in line with current guidelines, if any, since at least 4 weeks (e.g., physical exercise counseling, medication\u002Fsupplementation, nutritional counseling, psychosocial counseling)\n10. Expectedly to keep level of activity (including e.g. work\u002Feducational activities, physical activity) and dietary habits during the study, including caffeine consumption and liquid intake\n11. Negative pregnancy test at V1 and willingness to use a reliable method of contraception during the study in women of childbearing potential\n12. Readiness and ability to understand and comply with study requirements as judged by the investigator (to take the IP as recommended)\n\nExclusion Criteria\n\n1. Rapidly progressing cancer without reasonable treatment options and\u002For serious worsening of cancer disease during the study, as well as the need for any cancer treatment that expectedly may need to start and\u002For cancer-related fatigue management that expectedly may need to start\u002Fget modified during the study\n2. Severe anemia (hemoglobin (Hb) ≤ 8 g\u002Fdl within last 2 weeks before or at visit 1\n3. Acute illness or uncontrolled chronic metabolic illness (including diabetes mellitus, hyperthyroidism, hypothyroidism, and excluding adequately medicated hypothyroidism), uncontrolled pain, and other disorders known to cause fatigue complaints (such as heart failure, chronic obstructive pulmonary disease (COPD), severe deconditioning and\u002For sarcopenia, severe and unresponsive inflammation, severe damage of gastrointestinal organs impairing oral food intake and digestion, parenteral nutrition, decreased calorie intake due to substantial appetite loss), all as per investigator's judgment\n4. Psychiatric disorders, including recently occurred (within the last 12 weeks before visit 1) or severe depression as judged by the investigator (stable treatment with low-dose selective serotonin reuptake inhibitors (SSRIs) is permitted)\n5. Known HIV infection, hepatitis B or C, or active tuberculosis (self-reported)\n6. Major surgery within 4 weeks before study or planned surgery during the treatment period\n7. Consuming any other food supplements \u002F FSMPs during the study, e.g. ginseng, guarana, mistletoe\n8. History of or current abuse of medication, e.g. opioids, drugs, or alcohol\n9. Participation in another study during the last 30 days before and during the study\n10. Breastfeeding\n11. Any other reason for exclusion as per the investigator's judgment, e.g. hypersensitivity or allergy to the IP, (expected) insufficient compliance with study procedures (due to substantial cognitive complaints related to cancer-related fatigue or other cause)","65 Years",{"count":262,"type":22},30,[65],"Effects of a food product containing mushroom extracts (AndoSanTM) in subjects with colorectal cancer-related fatigue.\n\nAndoSanTM is a specialized liquid food product that includes fermented extracts from the fungi Agaricus subrufesence (Agaricus blazei Murill), Hericium erinaceus, and Grifola frondosa as the main ingredients.\n\nThe primary study objective is to assess the change in complaints about cancer-related fatigue while taking AndoSanTM. Further objectives are to evaluate the change in health-related quality of life (QoL) and levels",[29],[69,267,268,269,270,271,272,273,274],"Colorectal cancer","Andosan","Agaricus blazei Murill","Hericium erinaceus","Agaricus subrufesence","Mushroom extract","Grifola frondosa","Chronic inflammation","2024-09-18",{"date":277,"type":46},"2024-09-20",{"date":279,"type":46},"2024-09-09",{"date":281,"type":22},"2025-02",{"name":283,"class":227},"Mycotech Pharma AS",3,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":217,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":207,"minAge":61,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100545411","phase-4-cancer-related-fatigue-in-patients-with-breast-cancer-treatment-with-zhengyuan-capsules-100545411","NCT06381557","Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules","A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study on the Effectiveness and Safety of Zhengyuan Capsules for Cancer-related Fatigue in Patients With Breast Cancer","Inclusion Criteria:\n\n1. Histopathologically or cytologically confirmed as breast cancer; AJCC 8th edition staging for breast cancer is stages I to III, clinically and radiologically confirmed with no tumor recurrence or metastasis.\n2. Completed anti-tumor treatment (surgery, radiotherapy, chemotherapy, targeted therapy) for at least 2 months, with no planned anti-tumor treatment during the study period, excluding endocrine therapy.\n3. Meets the diagnosis criteria for cancer-related fatigue.\n4. Average score on the Brief Fatigue Inventory (BFI) in the 14 days preceding enrollment is ≥4.\n5. Life expectancy of at least 6 months.\n6. Age between 18 and 70 years old.\n7. Patients and their families understand the basic details of the study, agree to cooperate in completing the relevant research; the patient can communicate verbally and in writing; voluntary signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of significant liver or kidney dysfunction (e.g., alanine transaminase, aspartate transaminase greater than 3 times the upper limit of normal, blood creatinine greater than 1.5 times the upper limit of normal, eGFR \\<60 mL\u002Fmin\u002F1.73m²) or abnormalities in the hematological system (platelet count \\<75×10⁹\u002FL, hemoglobin \\<100g\u002FL, or neutrophil count \\<1.5×10⁹\u002FL);\n2. Presence of severe primary diseases in the cardiovascular, cerebrovascular, immune systems, or requiring treatment for mental illness;\n3. Hypokalemia (blood potassium \\<3.0mmol\u002FL) or electrolyte imbalance with related symptoms or symptoms that may occur after enrollment;\n4. Unimproved hypothyroidism;\n5. Hypoalbuminemia (blood albumin \\<30g\u002FL) or malnutrition (Body Mass Index, BMI \\<18 kg\u002Fm²);\n6. Traditional Chinese medicine syndrome pattern consistent with Yin deficiency and internal heat;\n7. Use of medications indicated in the instructions or with main functions that meet the following conditions: other Western or Chinese medicine preparations that affect the efficacy evaluation of cancer-related fatigue; undergoing treatment with anti-anemia, anti-anxiety\u002Fdepression, anti-insomnia, or other psychostimulant drugs; use of drugs with leukocyte-increasing effects within the past week, such as granulocyte colony-stimulating factor (G-CSF);\n8. Known allergy to the investigational drug or its components;\n9. Breastfeeding, pregnant, or planning to become pregnant within 3 months;\n10. The investigator deems the individual unsuitable for participation in this clinical trial.","70 Years",{"count":294,"type":22},240,[296],"PHASE4","Traditional Chinese medicine（TCM） has achieved some meaningful results in improving the symptoms and quality of life of cancer patients, but many research results need to be further verified by clinical trials with larger samples and better design.This study aims to investigate effectiveness and safety of Zhengyuan Capsules for cancer-related fatigue in patients with breast cancer.",[29],"2024-04-22",{"date":301,"type":46},"2024-04-24",{"date":303,"type":22},"2024-05-01",{"date":305,"type":22},"2027-03-01",{"name":307,"class":53},"Qiang Fu","Cancer-Related Fatigue"]